HL Financial Services LLC reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 30.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,867 shares of the medical equipment provider’s stock after selling 3,970 shares during the quarter. HL Financial Services LLC’s holdings in Zimmer Biomet Holdings were worth $1,038,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Bronfman E.L. Rothschild L.P. lifted its stake in shares of Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares during the last quarter. Parkside Financial Bank & Trust increased its position in Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares in the last quarter. BB&T Investment Services Inc. acquired a new position in Zimmer Biomet Holdings during the 2nd quarter valued at about $144,000. Sandy Spring Bank increased its position in Zimmer Biomet Holdings by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 66 shares in the last quarter. Finally, Grove Bank & Trust increased its position in Zimmer Biomet Holdings by 346.1% during the 2nd quarter. Grove Bank & Trust now owns 1,316 shares of the medical equipment provider’s stock valued at $169,000 after buying an additional 1,021 shares in the last quarter. Hedge funds and other institutional investors own 85.44% of the company’s stock.

WARNING: “HL Financial Services LLC Has $1.04 Million Position in Zimmer Biomet Holdings, Inc. (ZBH)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.watchlistnews.com/hl-financial-services-llc-has-1-04-million-position-in-zimmer-biomet-holdings-inc-zbh/1700083.html.

Zimmer Biomet Holdings, Inc. (ZBH) traded down $1.09 during midday trading on Monday, hitting $110.75. The stock had a trading volume of 973,400 shares, compared to its average volume of 1,366,571. The stock has a market capitalization of $22,360.00, a P/E ratio of 13.72, a PEG ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.49. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.02). The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the business earned $1.79 EPS. research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

ZBH has been the topic of several recent analyst reports. Morgan Stanley upped their target price on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday, July 17th. Zacks Investment Research lowered Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. BidaskClub lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Canaccord Genuity lowered Zimmer Biomet Holdings from a “buy” rating to a “hold” rating and reduced their target price for the company from $141.00 to $135.00 in a research report on Friday, July 28th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $135.00 price objective on shares of Zimmer Biomet Holdings in a report on Friday, July 28th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Zimmer Biomet Holdings currently has a consensus rating of “Hold” and an average target price of $134.00.

Zimmer Biomet Holdings Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.